Business, Health Care, Local News

Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) as second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma

First immunotherapy to be approved for a gastroesophageal cancer in the European Union Approval based on Phase 3 ATTRACTION-3 trial showing statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today

Business, Health Care

ADC Therapeutics announces FDA accepts Biologics License Application and grants priority review for loncastuximab tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma

Prescription Drug User Fee Act target action date of May 21, 2021 LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with

Business, Health Care

The Bristol Myers Squibb Foundation and National Medical Fellowships launch $100 million program to help increase diversity and inclusion in clinical trials

Initiative will train 250 new clinical investigators and work within communities to build capacity to serve underrepresented patient populations PRINCETON, N.J.–(BUSINESS WIRE)–The Bristol Myers Squibb Foundation and National Medical Fellowships today announced that they have entered into a partnership aimed at improving